Global Blood Therapeutics (GBT), a clinical-stage biopharma focused on developing novel therapeutics for blood-based disorders, is discontinuing its GBT440 program for the treatment of idiopathic pulmonary fibrosis (IPF). The decision came after GBT evaluated the results from three studies, including one Phase 1 study and two Phase 2a…
Global Blood Therapeutics Ceases GBT440 Research Program for IPF
One of the hard, but necessary things that we face as a PF patient is our mortality. I am very aware of my shortened life span, and think about every day. This reality guides how I spend my time, energy, and the decisions I make. It also…
Everyone suffers from stress from time to time but when you have a chronic disease, stress not only adds to your everyday burden but can often exacerbate the symptoms of your condition. While we can’t avoid stress altogether, there are ways that we help ourselves relax more and not let things…
If anyone reading this column resides in southwestern Ontario, you can attest to the abnormally hot temperatures that landed on us toward the end of September. For those of you who can bear the heat and humidity, I do hope you had the chance to go outside, because…
More therapies are now available for the 30 million or so people with rare diseases in the U.S. than ever before, and millions of dollars are being invested in clinical studies that will test new ways of evaluating — and advancing — potential treatments, including the use of natural history…
The diabetes therapy vildagliptin reduces lung scarring after bacteria-related lung damage, according to a study in mice. It does this by preventing endothelial cells that line lung blood vessels from transforming themselves into stem cells — a process lungs use to protect themselves from the bacteria-related attack, known as an…
Results from the RECAP clinical trial, which was conducted over five years, support the long-term safety of Esbriet (pirfenidone) in patients with idiopathic pulmonary fibrosis (IPF). The study, “An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP),” was recently published in…
When talking to others about things they would like to do someday, it is common to hear people respond with, “That’s on my bucket list.” Whether it’s traveling around the world, seeking adventure in another country, or trying a daredevil-type activity such as skydiving or bungee jumping, people…
It probably won’t come as a surprise to hear that living with a chronic illness is difficult. Chronic illness not only impacts patients physically, but emotionally, socially, mentally and financially. To say that it can be challenging to navigate how to live with a chronic illness is an understatement. In…
Patients with idiopathic pulmonary fibrosis (IPF) are likely to experience symptoms for years before their diagnosis, a British study reports. University of Nottingham researchers analyzed symptoms in the medical charts of newly diagnosed patients to reach their conclusion. Breathlessness was the most common symptom, the team found. The research,…
